Cargando…
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
BACKGROUND: Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were s...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1712353/ https://www.ncbi.nlm.nih.gov/pubmed/17150109 http://dx.doi.org/10.1186/1471-2407-6-278 |